KR890701137A - 점막통과 전달제제 및 이들의 제조방법 - Google Patents

점막통과 전달제제 및 이들의 제조방법

Info

Publication number
KR890701137A
KR890701137A KR1019890700845A KR890700845A KR890701137A KR 890701137 A KR890701137 A KR 890701137A KR 1019890700845 A KR1019890700845 A KR 1019890700845A KR 890700845 A KR890700845 A KR 890700845A KR 890701137 A KR890701137 A KR 890701137A
Authority
KR
South Korea
Prior art keywords
formulation
monosaccharide
cyclodextrin
insulin
group
Prior art date
Application number
KR1019890700845A
Other languages
English (en)
Inventor
안디스 로버트 쇠렌센
안내 엥게스가드
필립 애드가 한센
Original Assignee
안내 세케르
노보 인더스트리 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK477487A external-priority patent/DK477487D0/da
Priority claimed from DK682587A external-priority patent/DK682587D0/da
Application filed by 안내 세케르, 노보 인더스트리 에이/에스 filed Critical 안내 세케르
Publication of KR890701137A publication Critical patent/KR890701137A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

내용 없음

Description

점막통과 전달제제 및 이들의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 하나 이상의 당류 또는 이들의 대사산물로 이루어지는 흡수향상부형제와 제약유효제로 이루어지며, 당류는 C3- C8을 함유하는 단당류와 6 내지 16단당류, 바람직하게는 글루코실, 잔기를 함유하는 과당류로 이루어지는 군으로부터 선택됨을 특징으로 하는 비 - 장경유, 점막통과 약제전달용제제.
  2. 제 1 항에 있어서, 단당류가 테트로오스, 펜토오스, 헥소오스 및 헵토오스로 이루어지는 군으로부터 선택됨을 특징으로 하는 제제.
  3. 제 2 항에 있어서, 단당류가 D - 에리트로오스, D - 리보오스, D - 리불로오스, D - 크실로오스, D - 릭소오스, D - 아라비노오스, D - 만노오스, D - 소르보오스 또는 D - 세도헵툴로오스 임을 특징으로 하는 제제.
  4. 제 3 항에 있어서, 단당류가 D - 릭소오스, D - 크실로오스, D - 리보오스, D - 만노오스 또는 L - 소르보오스임을 특징으로 하는 제제.
  5. 제 1 항에 있어서, 과당류가 α- 시클로덱스트린, β- 시클로덱스트린, γ- 시클로덱스트린 및 측쇄의 시클로덱스트린으로 이루어지는 군으로부터 선택됨을 특징으로 하는 제제.
  6. 제 5 항에 있어서, 과당류가 α- 또는 β- 시클로덱스트린임을 특징으로 하는 제제.
  7. 제1 - 6항에 있어서, 제약 유효제가 폴리펩티드임을 특징으로 하는 제제.
  8. 제 7 항에 있어서, 폴리펩티드가 인슐린, 인슐린유도체, 인슐린 혼합물 및 적어도 하나의 인슐린 유도체, 또는 인슐린유도체의 혼합물임을 특징으로 하는 제제.
  9. 제 8 항에 있어서, 인슐린함량이 제제그램당 5 내지 10000, 바람직하게는 50 내지 5000 국제단위 범위임을 특징으로 하는 제제.
  10. 제 7 항에 있어서, 폴리펩티드가 글루카곤임을 특징으로 하는 제제.
  11. 제10항에 있어서, 글루카곤함량이 제제그램당 0.1 내지 800, 바람직하게는 1 내지 600 밀리그램임을 특징으로 하는 제제.
  12. 제1 - 6항에서 정의된 하나 이상의 당류 및, 임의로, 가루상, 밀랍상 또는 액체 희석제, pH - 버퍼화제, 방부제 및 삼투압조절제로 이루어지는 군으로부터 선택된 하나 또는 그 이상의 보조제로 이루어지는 부형제의 제약유효제를 분산시키는 것으로 이루어지는, 비 - 장경유, 점막통과 약제전달용 제제의 제조방법.
  13. 이상에서 설명한 모든 신규특징 또는 특징들의 조합.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890700845A 1987-09-14 1988-09-14 점막통과 전달제제 및 이들의 제조방법 KR890701137A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK4774/87 1987-09-14
DK477487A DK477487D0 (da) 1987-09-14 1987-09-14 Praeparat
DK6825/87 1987-12-23
DK682587A DK682587D0 (da) 1987-12-23 1987-12-23 Praeparat til non-parenteral administration og fremgangsmaade til dets fremstilling
PCT/DK1988/000151 WO1989002279A1 (en) 1987-09-14 1988-09-14 Trans-mucosal delivery formulations and a method for preparation thereof

Publications (1)

Publication Number Publication Date
KR890701137A true KR890701137A (ko) 1989-12-19

Family

ID=26067617

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890700845A KR890701137A (ko) 1987-09-14 1988-09-14 점막통과 전달제제 및 이들의 제조방법

Country Status (11)

Country Link
EP (1) EP0308181A1 (ko)
JP (1) JPH03502920A (ko)
KR (1) KR890701137A (ko)
CN (1) CN1031940A (ko)
AU (1) AU2481688A (ko)
CS (1) CS274435B2 (ko)
FI (1) FI901256A0 (ko)
HU (1) HUT53281A (ko)
PT (1) PT88490B (ko)
WO (1) WO1989002279A1 (ko)
YU (1) YU173088A (ko)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005535A1 (en) * 1988-11-14 1990-05-31 Otsuka Pharmaceutical Co., Ltd. Interferon preparation for nasal administration
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
IT1248725B (it) * 1990-06-12 1995-01-26 Sclavo Spa Composizione farmaceutica in polvere per somministrazione per via nasale contenente essenzialmente calcitonina ed un eccipiente idrosolubile
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
NL9001681A (nl) * 1990-07-24 1992-02-17 Rijksuniversiteit Transmucosale geneesmiddelpreparaten en transmucosale toediening.
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
BE1006873A6 (nl) * 1993-03-26 1995-01-10 Merkus Franciscus W H M Toedieningsformulering voor nasale insuline toediening.
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
AU2104097A (en) * 1996-03-13 1997-10-01 Glaxo Group Limited Medicaments comprising 5ht1-like receptor agonists with an increased absorption
EP0983769A4 (en) 1997-04-14 2002-05-02 Mitsubishi Tokyo Pharm Inc PERMUCOSE FORMULATION
TWI243687B (en) * 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
WO1999059543A1 (en) 1998-05-20 1999-11-25 Highchem Company., Ltd. A pharmaceutical formulation for nasal administration
EP0998940A1 (en) * 1998-09-30 2000-05-10 Laboratoire Theramex Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
CN1299770C (zh) * 2004-05-31 2007-02-14 刘近周 多功能鼻腔和鼻窦洁疗液
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
SE533540C2 (sv) * 2008-12-19 2010-10-19 Neoinvent Medical Engineering Ab Administrerinssystem för administrering av en substans i munhålan
EP2662472B1 (de) 2009-03-31 2019-02-27 Boehringer Ingelheim International Gmbh Verfahren zur Beschichtung einer Oberfläche eines Bauteils
US9265910B2 (en) 2009-05-18 2016-02-23 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064164A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
EP2585151B1 (en) 2010-06-24 2018-04-04 Boehringer Ingelheim International GmbH Nebulizer
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
EP2970444A4 (en) 2013-03-13 2016-11-09 Seattle Genetics Inc CYCLODEXTRIN AND ANTIBODY ACTIVE CONJUGATE FORMULATIONS
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
CA2948071C (en) 2014-05-07 2022-08-30 Boehringer Ingelheim International Gmbh Container, nebulizer and use
PE20161564A1 (es) 2014-05-07 2017-01-25 Boehringer Ingelheim Int Nebulizador, dispositivo indicador y recipiente
ES2874029T3 (es) 2014-05-07 2021-11-04 Boehringer Ingelheim Int Nebulizador
MD3258919T3 (ro) * 2015-02-17 2023-04-30 Lilly Co Eli Formulare de pulbere nazală pentru tratamentul hipoglicemiei

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE38604B1 (en) * 1972-12-05 1978-04-26 Ono Pharmaceutical Co Prostaglandin compositions
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS5921613A (ja) * 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
DE3302319A1 (de) * 1983-01-25 1984-08-16 Karl Eugen Prof. Dr.Med. Theurer Verfahren zur konservierung, stabilisierung und resorptionsverbesserung von therapeutisch anzuwendenden zell- und organbestandteilen
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
JPS61126034A (ja) * 1984-11-26 1986-06-13 Yamanouchi Pharmaceut Co Ltd アルド−スを含有するカルシトニン経鼻剤
US4727077A (en) * 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
JPS63196524A (ja) * 1987-02-10 1988-08-15 Wakunaga Pharmaceut Co Ltd 経粘膜吸収型制ガン作用調節剤

Also Published As

Publication number Publication date
CS274435B2 (en) 1991-04-11
YU173088A (en) 1990-06-30
WO1989002279A1 (en) 1989-03-23
CS614388A2 (en) 1990-08-14
AU2481688A (en) 1989-04-17
HUT53281A (en) 1990-10-28
CN1031940A (zh) 1989-03-29
HU885826D0 (en) 1990-09-28
FI901256A0 (fi) 1990-03-13
JPH03502920A (ja) 1991-07-04
EP0308181A1 (en) 1989-03-22
PT88490B (pt) 1992-11-30
PT88490A (pt) 1988-10-01

Similar Documents

Publication Publication Date Title
KR890701137A (ko) 점막통과 전달제제 및 이들의 제조방법
US5661130A (en) Absorption enhancers for drug administration
Sachdeo et al. Steady‐state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy
Brogden et al. Human insulin: a review of its biological activity, pharmacokinetics and therapeutic use
US5977082A (en) Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
PT93847A (pt) Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
EP2330092A3 (en) Medicament comprising steviol or isosteviol for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
PE19496A1 (es) Formulacion de analogo de insulina humana
AR012995A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de medicamentos y composiciones farmaceuticas que contienedichos compuestos.
IL87149A (en) 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
KR920701249A (ko) 글리코실화 인슐린
KR880002515A (ko) 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물
Petley et al. The pharmacokinetics of nicotinamide in humans and rodents
AU2545588A (en) Sucralose compositions
NO179601C (no) Anvendelse av sulfatiserte sakkarider i fremstilling av et preparat for hårpleie
US20030130205A1 (en) Novel pharmaceutical anti-infective agents containing carbohydrate moieties and methods of their preparation and use
KR910011278A (ko) 은행잎 액기스 함유 수용액
AU9133691A (en) Beverage for preoperative intake
KR940021067A (ko) 에너지 보충 당류원 및 그 용도
SE512881C2 (sv) Bruksfärdiga injektionslösningar innehållande en antitumörantracyklinglykosid
LERNER The augmentation effect of secretin on the insulin responses to known stimuli: specificity for glucose
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
WO1994022461A1 (en) Formulation for nasal insulin delivery
Johnston et al. Effects of SMS 201-995 on intermediary metabolism and endocrine status in normal and diabetic humans
Kivistö et al. Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid